糖鎖に関わる応用研究の潮流と展開 : 抗体医薬
スポンサーリンク
概要
著者
-
SHITARA Kenya
Tokyo Research Laboratories, Kyowa Hakko Kogyo
-
Hanai Nobuo
Biowa Inc.
-
Shitara Kenya
Department Of Antibody Research Pharmaceutical Research Center Kyowa Hakko Kogyo Co. Ltd.
-
Shitara Kenya
Tokyo Research Laboratories Kyowa Hakko Kogyo
-
Shitara Kenya
Tokyo Research Laboratories Kyowa Hakko Kogyo Co. Ltd.
-
SATOH Mitsuo
Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd.
-
Satoh Mitsuo
Antibody Research Laboratories Kyowa Hakko Kirin Co. Ltd
-
Shitara Kenya
Department Of Strategic Product Planning Kyowa Hakko Kirin Co. Ltd
-
Satoh Mitsuo
Tokyo Research Laboratories Kyowa Hakko Kogyo Co. Ltd.
関連論文
- Mouse-Human Chimeric Anti-Tn IgG1 Induced Anti-tumor Activity against Jurkat Cells in Vitro and in Vivo(Pharmacology)
- Further investigation of the epitope recognized by the new monoclonal antibody 2C9
- 糖鎖に関わる応用研究の潮流と展開 : 抗体医薬
- Enhanced Fc-Dependent Cellular Cytotoxicity of Fc Fusion Proteins Derived from TNF Receptor II and LFA-3 by Fucose Removal from Asn-Linked Oligosaccharides
- Fucose Removal from Complex-Type Oligosaccharide Enhances the Antibody-Dependent Cellular Cytotoxicity of Single-Gene-Encoded Bispecific Antibody Comprising of Two Single-Chain Antibodies Linked to the Antibody Constant Region
- Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity
- Engineered therapeutic antibodies with improved effector functions